RA
CASI

Royce & Associates’s CASI Pharmaceuticals CASI Stock Holding History

Royce & Associates’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,874
Closed -$368K – 1153
2018
Q3 		$368K Sell
7,874
-4,126
-34% -$288K ﹤0.01% 990
2018
Q2 		$988K Buy
+12,000
New +$810K 0.01% 944

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Royce & Associates's CASI Position: Q4 2018 in Review

Royce & Associates sold out of CASI Pharmaceuticals (CASI) in Q4 2018, closing a stake of 7,874 shares — an estimated $368K sold.

Royce & Associates first reported a position in CASI in Q2 2018 and held it in 2 quarters. The position peaked at $988K in Q2 2018. 54 funds tracked by Wall St. Rank hold CASI as of Q4 2018.

  • Royce & Associates reported no remaining CASI Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Royce & Associates sold 7,874 CASI Pharmaceuticals shares in Q4 2018, an estimated $368K.
  • Royce & Associates first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Royce & Associates's CASI Pharmaceuticals position peaked at $988K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2018.

Based on Royce & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.